For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$155.01
Thesis
Novartis is a focused innovative-medicines company and the clear leader in radioligand therapy. Pluvicto and Lutathera anchor a radiopharma franchise that is genuinely hard to replicate — it depends on isotope supply, specialized manufacturing, and dosing logistics that few competitors can match, giving Novartis a durable moat in a fast-growing modality.
Beyond radiopharma, a deep cardiovascular and immunology portfolio (Entresto, the inclisiran RNA therapeutic Leqvio, Cosentyx) backs the growth, and the company has shed non-core units — generics, consumer health, its Roche stake — to concentrate on patented drugs. The risks are patent cliffs (notably Entresto) and the usual pipeline-execution and pricing pressures.
Catalysts
- Radioligand-therapy scale-up and new indications
- Pipeline readouts across CV, immunology, oncology
- Entresto patent cliff and loss-of-exclusivity management
- Manufacturing capacity for radiopharmaceuticals
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 21Financial resultsSEC
Novartis AG filed Form 6-K containing quarterly financial information for period ended June 30, 2026.